Literature DB >> 19040340

Treatment options for esophageal cancer.

Thomas J Murphy1, Narayamasamy Ravi, John V Reynolds.   

Abstract

There is considerable controversy over the level of evidence from randomized trials underpinning management decisions for patients presenting with localized cancer of the esophagus and esophago-gastric junction. There is also an optimism that new drugs and new approaches, including response prediction based on sequential (18)FDG-PET scanning following induction chemotherapy, may improve treatments pathways and outcomes. In this review we assess the level of evidence from the major published trials, and discuss new trials and approaches.

Entities:  

Mesh：

Year:  2008        PMID： 19040340     DOI： 10.1517/14656560802560237

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  6 in total

1.  Mutations in Fanconi anemia genes and the risk of esophageal cancer.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Pierre Lepage; David Roquis; Ali R Sadjadi; Karim Aghcheli; Abbas Yazdanbod; Ramin Shakeri; Jafar Bashiri; Masoud Sotoudeh; Akram Pourshams; Parviz Ghadirian; Steven A Narod
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

2.  Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; Becky A Bibby; Ann Marie Mongan; Laure Marignol; Christian N Paxton; Katherine Geiersbach; Mary P Bronner; Jacintha O'Sullivan; John Reynolds; Stephen G Maher
Journal:  Mol Med       Date:  2016-05-23       Impact factor: 6.354

3.  MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.

Authors:  Niamh Lynam-Lennon; Susan Heavey; Gary Sommerville; Becky A S Bibby; Brendan Ffrench; Jennifer Quinn; Claudia Gasch; John J O'Leary; Michael F Gallagher; John V Reynolds; Stephen G Maher
Journal:  Oncotarget       Date:  2017-02-14

4.  Innovative Technologies Changing Cancer Treatment.

Authors:  Sara Charmsaz; Maria Prencipe; Maeve Kiely; Graham P Pidgeon; Denis M Collins
Journal:  Cancers (Basel)       Date:  2018-06-19       Impact factor: 6.639

5.  Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: case report of a surgically challenging condition.

Authors:  Namita Jayaprakash; Fardod O'Kelly; Kheng Tian Lim; John Vincent Reynolds
Journal:  Patient Saf Surg       Date:  2009-09-28

6.  Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; Stephen G Maher; Aoife Maguire; James Phelan; Cian Muldoon; John V Reynolds; Jacintha O'Sullivan
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.